Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20589967 | 1.00 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL24514516 | 0.88 | ALDH1A1 (0.50) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL30744367 | 0.80 | CETP (0.46) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL9841010 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPK1TDP1L3MBTL1MMP1 | |
| SCHEMBL26988864 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPK1TDP1L3MBTL1MMP1 | |
| SCHEMBL9841014 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPK1TDP1L3MBTL1MMP1 | |
| SCHEMBL22692563 | 0.79 | CETP (0.45) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL8513270 | 0.79 | CETP (0.45) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL28110794 | 0.78 | ALDH1A1 (0.46) | CETPALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL10949172 | 0.78 | CETP (0.52) | CETPALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| EP-3638678-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | CETP 40/4885ALDH1A1 4687/4885CYP3A4 4867/4885 |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | CETP 40/4885ALDH1A1 4687/4885CYP3A4 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.